RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-01-14 | 2022-01-13+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +341.0K | 277.5K | New | $0 |
| DM | 2022-01-14 | 2022-01-13+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $13.76 | -341.0K | 23.5K | -94% | -$4.69M |
| 2022-01-05 | 2022-01-03 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +659 | 597.9K | +0.1% | $0 | |
| 2022-01-05 | 2022-01-03 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +555 | 7.66M | +0.0% | $0 | |
| 2022-01-05 | 2022-01-04 | RXRX | Borgeson Blake | Dir | S - Sale | $18.03 | -9,625 | 7.65M | -0.1% | -$173.5K | |
| 2022-01-05 | 2022-01-03 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +763 | 134.6K | +0.6% | $0 | |
| 2022-01-05 | 2022-01-03 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +1,040 | 8,669 | +14% | $0 | |
| 2022-01-05 | 2022-01-03 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +589 | 1,370 | +75% | $0 | |
| D | 2022-01-05 | 2022-01-03 | RXRX | Doyle Ramona | Chief Medical Off | M - OptEx | $2.47 | +40.3K | 40.3K | New | +$99.6K |
| 2022-01-05 | 2022-01-03 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +693 | 7,862 | +10% | $0 | |
| 2021-12-23 | 2021-12-21 | RXRX | Borgeson Blake | Dir | S - Sale | $18.75 | -9,625 | 7.66M | -0.1% | -$180.5K | |
| D | 2021-12-20 | 2021-12-16 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +200 | 23.7K | +0.9% | $0 |
| D | 2021-12-20 | 2021-12-16 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $20.01 | -200 | 23.5K | -0.8% | -$4,002 |
| M | 2021-12-20 | 2021-12-16 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale | $18.74 | -2,500 | 48.8K | -5% | -$46.9K |
| D | 2021-12-15 | 2021-12-13 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100 | 23.6K | +0.4% | $0 |
| D | 2021-12-15 | 2021-12-13 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $20.02 | -100 | 23.5K | -0.4% | -$2,002 |
| DM | 2021-12-10 | 2021-12-08+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $20.14 | -11.8K | 23.5K | -33% | -$236.6K |
| D | 2021-12-10 | 2021-12-08 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.47 | +28.6K | 28.6K | New | +$70.8K |
| DM | 2021-12-10 | 2021-12-08+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +6,574 | 29.0K | +29% | $0 |
| 2021-12-09 | 2021-12-07 | RXRX | Lux Co-Invest Partners, LLC | Former 10% Owner | J - Other | $0.00 | -4.27M | 13.02M | -25% | $0 | |
| MI | 2021-12-09 | 2021-12-07 | RXRX | Li Dean Y | Dir | S - Sale | $20.48 | -15.9K | 1.32M | -1% | -$325.6K |
| M | 2021-12-09 | 2021-12-07 | RXRX | Borgeson Blake | Dir | S - Sale | $20.31 | -9,625 | 7.68M | -0.1% | -$195.5K |
| MAI | 2021-12-09 | 2021-11-17+ | RXRX | Li Dean Y | Dir | S - Sale | $20.15 | -19.1K | 1.33M | -1% | -$384.9K |
| 2021-12-09 | 2021-12-07 | RXRX | Dar Zavain | Dir | J - Other | $0.00 | +3,599 | 3,599 | New | $0 | |
| MI | 2021-12-09 | 2021-12-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $20.51 | -3,125 | 146.9K | -2% | -$64.1K |
| M | 2021-12-09 | 2021-12-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $20.48 | -16.7K | 8.20M | -0.2% | -$341.3K |
| 2021-12-09 | 2021-11-21 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -1.10M | 8.22M | -12% | $0 | |
| MI | 2021-12-09 | 2021-11-21 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | +1.10M | 550.0K | New | $0 |
| M | 2021-11-22 | 2021-11-18 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale | $18.92 | -2,500 | 50.0K | -5% | -$47.3K |
| M | 2021-11-22 | 2021-11-18 | RXRX | Borgeson Blake | Dir | S - Sale | $18.91 | -9,625 | 7.68M | -0.1% | -$182.0K |
| M | 2021-11-19 | 2021-11-17+ | RXRX | Li Dean Y | Dir | S - Sale | $20.15 | -19.1K | 591.6K | -3% | -$384.9K |
| 2021-10-05 | 2021-10-01 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +295 | 781 | +61% | $0 | |
| 2021-10-05 | 2021-10-01 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +858 | 7,629 | +13% | $0 | |
| 2021-10-05 | 2021-10-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +543 | 597.3K | +0.1% | $0 | |
| 2021-10-05 | 2021-10-01 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +457 | 7.69M | +0.0% | $0 | |
| 2021-10-05 | 2021-10-01 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +629 | 133.8K | +0.5% | $0 | |
| 2021-10-05 | 2021-10-01 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +572 | 7,169 | +9% | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +521 | 6,771 | +8% | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +278 | 7.69M | +0.0% | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +347 | 6,597 | +6% | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +295 | 295 | New | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +382 | 133.2K | +0.3% | $0 | |
| 2021-07-06 | 2021-07-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +330 | 596.7K | +0.1% | $0 |
Purchase Sale Sale after option exercise All abbreviations